about
Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses.Platelet kinetic study in patients with idiopathic thrombocytopenic purpura (ITP) refractory or relapsing after corticosteroid treatment.Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.SDF-1 inhibition targets the bone marrow niche for cancer therapy.The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project.Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.Combined DOCK8 and CLEC7A mutations causing immunodeficiency in 3 brothers with diarrhea, eczema, and infections.Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).Candidate genes of Waldenström's macroglobulinemia: current evidence and research.High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.Stem cell mobilization in HIV seropositive patients with lymphoma.Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.Neoplasms derived from plasmacytoid dendritic cells.Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients.P. aeruginosa bloodstream infections among hematological patients: an old or new question?Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients.Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution.Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies.Uncontrolled-rate freezing of peripheral blood progenitor cells allows successful engraftment by sparing primitive and committed hematopoietic progenitors.Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience.Relapsing bloodstream infections during treatment of acute leukemia.Immune-mediated hepatitis-associated aplastic anemia caused by the emergence of a mutant hepatitis B virus undetectable by standard assays.A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione ItaliaExome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia.Differences among young adults, adults and elderly chronic myeloid leukemia patients.SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.
P50
Q30428311-5F5384FE-3088-4060-A54F-835C425B73B4Q33343171-15505C3A-B52E-4B32-B2AF-0793216339E4Q33371939-A16A662A-81C1-40A6-AE5E-2CFF0DDC13CEQ33408772-9F4D056C-AD5E-49C3-BEAB-4037E6270AE0Q33415354-292307D3-6AAD-4C23-9412-E64FCC77C348Q34324830-07AEBB40-20DC-47F7-A549-1B0AFD365143Q35193749-F950602A-3B69-42A7-AEFC-5349B9141E4DQ35925639-B5AF1BCC-07E7-43E8-9B18-82B89B2560DFQ36528379-F0CAD21C-4F9D-44E6-ADF2-69DE4D124DFBQ36605603-FFE99A94-E219-451B-A899-65331C915E05Q36715906-04BEA3CE-7841-4F1A-8394-DEB5548B9965Q37074275-CCCB2369-E491-403D-8DC1-2590D8AB739AQ37273182-EB1B8560-753E-46DB-9394-B43C1BAD253CQ37273199-0DD55563-0083-4B2F-8C14-F16DA9F4570DQ37334956-37A6B2AB-8FCD-4140-ADF8-31893F6B60FEQ38689894-84E937F8-DF25-40BA-8BD1-BABE7BEC0FD1Q40102961-674EF257-D674-4855-AFB4-F923B492970FQ40295711-ED045A69-9E83-44AA-AABB-9DBF13995F4FQ40428787-08BAB80E-0664-435F-AC53-9CD71E9F43A3Q40459986-71A9B8B4-37E6-4AC5-B7F8-EEA7A49FD326Q40533740-78495AD5-7B86-4751-A2BA-2FFA41A2E07EQ40821920-39C7AE85-FE97-460E-B839-BE550756B66AQ40834878-744444CD-3B43-49C8-B357-36A90C09BDF2Q41156034-15153E76-2674-4624-B6CD-4A5FDBAF1863Q41291872-FFD84F3E-65EB-4029-80B3-C2B9BA1EBA26Q41948692-AC3910B3-4F5A-4453-BFF8-26FB7A8945A6Q43184611-DE5ADCF3-2446-431E-8360-03B0BF7D9623Q43808456-FF691C38-0951-43E5-AB32-EB1F598938E2Q44432312-E2B0F74F-A402-4AA2-9031-D480128D2B4EQ44457701-AC7AE97A-B613-4C95-A5C6-F541E2F068F5Q44701232-6AB6CAF3-1CA6-446E-B26D-383257E74CE3Q45009414-374F6A4B-9D93-4275-AC74-65EEBC8870B2Q45347202-66F7800B-FD36-4FEA-B24D-7A048817D39AQ45355151-CB38F46D-B92F-4BFA-9036-5554C161B216Q45406935-75A480A8-5091-405E-A972-0D8F78EA67E6Q45948421-4F3006CC-5B71-4327-9765-0FFE2E6971BEQ47741058-87E5C010-319A-41C1-846C-35CD6D091A2DQ48232462-C36A1ECF-4AEA-4CFC-8AD1-7D9F7B1F460BQ50848914-35A81087-6A85-421D-8BE6-211774DF68B7Q53058451-37956B98-D348-472A-BDA5-C5E46C05CCC3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Rossi
@ast
Giuseppe Rossi
@en
Giuseppe Rossi
@es
Giuseppe Rossi
@nl
Giuseppe Rossi
@sl
type
label
Giuseppe Rossi
@ast
Giuseppe Rossi
@en
Giuseppe Rossi
@es
Giuseppe Rossi
@nl
Giuseppe Rossi
@sl
prefLabel
Giuseppe Rossi
@ast
Giuseppe Rossi
@en
Giuseppe Rossi
@es
Giuseppe Rossi
@nl
Giuseppe Rossi
@sl
P106
P21
P31
P496
0000-0001-8377-2898